The impact of the dose of natural killer cells in the graft on severe acute graft-versus-host disease after unrelated bone marrow transplantation

Leukemia Research

Volumn 36, Issue 6, 2012, Pages 699-703

  Tanaka, Masatsugu ^a   Kobayashi, Shoichi ^a   Numata, Ayumi ^a   Tachibana, Takayoshi ^a   Takasaki, Hirotaka ^a   Maruta, Atsuo ^a   Ishigatsubo, Yoshiaki ^b   Kanamori, Heiwa ^a  

^a KANAGAWA CANCER CENTER   (Japan)

^b YOKOHAMA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Graft versus host disease; Natural killer cell; Unrelated bone marrow transplantation

Indexed keywords

CD56 ANTIGEN; CYCLOSPORIN A; METHOTREXATE; TACROLIMUS;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE LEUKEMIA; ADOLESCENT; ADULT; AGE; ARTICLE; BONE MARROW TRANSPLANTATION; CONTROLLED STUDY; DISEASE SEVERITY; ENGRAFTMENT; FEMALE; HLA MATCHING; HUMAN; JAPAN; LYMPHOCYTE SUBPOPULATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; MYELODYSPLASTIC SYNDROME; NATURAL KILLER CELL; NEUTROPHIL; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RELAPSE; UNRELATED DONORS;

ADOLESCENT; ADULT; ANTIGENS, CD34; BONE MARROW TRANSPLANTATION; FEMALE; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HUMANS; KILLER CELLS, NATURAL; LEUKOCYTE COUNT; MALE; MIDDLE AGED; NEUTROPHILS; SEVERITY OF ILLNESS INDEX; UNRELATED DONORS; YOUNG ADULT;

EID: 84859809525     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2011.11.009     Document Type: Article

References (15)

1. Kanda Y., Chiba S., Hirai H., Sakamaki H., Iseki T., Kodera Y., et al. Allogeneic hematopoietic stem cell transplantation from family members other than HLA-identical siblings over the last decade (1991-2000). Blood 2003, 102:1541-1547.
2. Lee S.J., Klein J., Haagenson M., Baxter-Lowe L.A., Confer D.L., Eapen M., et al. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood 2007, 110:4576-4583.
3. Kawase T., Morishima Y., Matsuo K., Kashiwase K., Inoko H., Saji H., et al. allele mismatch combinations responsible for severe acute graft-versus-host disease and implication for its molecular mechanism. Blood 2007, 110:2235-2241.
4. Aoudjhane M., Labopin M., Gorin N.C., Shimoni A., Ruutu T., Kolb H.J., et al. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT). Leukemia 2005, 19:2304-2312.
5. Kollman C., Howe C.W., Anasetti C., Antin J.H., Davies S.M., Filipovich A.H., et al. Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age. Blood 2001, 98:2043-2051.
6. Larghero J., Rocha V., Porcher R., Filion A., Ternaux B., Lacassagne M.N., et al. Association of bone marrow natural killer cell dose with neutrophil recovery and chronic graft-versus-host disease after HLA identical sibling bone marrow transplants. Br J Haematol 2007, 138:101-109.
7. Rocha V., Carmagnat M.V., Chevret S., Flinois O., Bittencourt H., Esperou H., et al. Influence of bone marrow graft lymphocyte subsets on outcome after HLA-identical sibling transplants. Exp Hematol 2001, 29:1347-1352.
8. Yamasaki S., Henzan H., Ohno Y., Yamanaka T., Iino T., Itou Y., et al. Influence of transplanted dose of CD56+ cells on development of graft-versus-host disease in patients receiving G-CSF-mobilized peripheral blood progenitor cells from HLA-identical sibling donors. Bone Marrow Transplant 2003, 32:505-510.
9. Iori A.P., Torelli G.F., De Propris M.S., Milano F., Pupella S., Gozzer M., et al. B-cell concentration in the apheretic product predicts acute graft-versus-host disease and treatment-related mortality of allogeneic peripheral blood stem cell transplantation. Transplantation 2008, 85:386-390.
10. Asai O., Longo D.L., Tian Z.G., Hornung R.L., Taub D.D., Ruscetti F.W., et al. Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation. J Clin Invest 1998, 101:1835-1842.
11. Olson J.A., Leveson-Gower D.B., Gill S., Baker J., Beilhack A., Negrin R.S. NK cells mediate reduction of GVHD by inhibiting activated, alloreactive T cells while retaining GVT effects. Blood 2010, 115:4293-4301.
12. Przepiorka D., Weisdorf D., Martin P., Klingemann H.G., Beatty P., Hows J., et al. 1994 consensus conference on acute GVHD grading. Bone Marrow Transplant 1995, 15:825-828.
13. Gray R.J. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988, 16:1141-1154.
14. Fine J.P., Gray R.J. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999, 94:496-509.
15. Scholl S., Mugge L.O., Issa M.C., Kasper C., Pachmann K., Hoffken K., et al. Impact of early NK cell recovery on development of GvHD and CMV reactivation in dose-reduced regimen prior to allogeneic PBSCT. Bone Marrow Transplant 2005, 35:183-190.